Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics Inc. (NASDAQ: CORT) generates frequent news as a commercial-stage pharmaceutical company focused on cortisol modulation in endocrinology, oncology, metabolic disease and neurology. Company updates often highlight progress with Korlym, which Corcept describes as the first FDA-approved medication for patients with endogenous hypercortisolism, and with a pipeline of selective glucocorticoid receptor antagonists and other cortisol modulators.
News about Corcept commonly covers clinical trial milestones in hypercortisolism, solid tumors, ALS and liver disease. Examples include data from the CATALYST program in patients with difficult-to-control type 2 diabetes and hypercortisolism, the pivotal ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, the BELLA Phase 2 trial in gynecologic cancers, the MONARCH Phase 2b trial in MASH, and the DAZALS trial of dazucorilant in ALS. Company communications also describe upcoming or ongoing studies of nenocorilant in combination with immunotherapy in solid tumors.
Investors following CORT news will see regular regulatory and corporate announcements, such as New Drug Application (NDA) submissions and FDA acceptance for review of relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application (MAA) to the European Medicines Agency, and an FDA Complete Response Letter requesting additional evidence of effectiveness for relacorilant in hypertension secondary to hypercortisolism. Quarterly earnings releases and corporate updates, reported via press releases and Form 8-K filings, provide information on product revenue from Korlym, operating expenses and the company’s cash and investment position.
This CORT news page on Stock Titan aggregates these public disclosures so readers can monitor Corcept’s clinical data presentations, regulatory milestones, financial results and other material events in one place. Users interested in endocrine disorders, ovarian cancer, MASH, ALS or cortisol biology can review the evolving news flow to understand how Corcept’s programs are progressing over time.
Corcept Therapeutics (NASDAQ: CORT) will present new genomic data on adrenocortical carcinoma at the 2020 AACR Annual Meeting, starting June 22. The data, which addresses excessive cortisol, is critical for their Phase 1b trial of relacorilant with pembrolizumab in patients with advanced cancer. This research aims to enhance immunotherapy's efficacy by mitigating cortisol's negative effects. The poster presentation is set for a virtual format and will be available online following the meeting.
Corcept Therapeutics reported Q1 2020 financial results with revenue of $93.2 million, up 44% year-over-year. GAAP net income rose to $30.1 million, with diluted EPS of $0.25. Non-GAAP diluted EPS was $0.34, compared to $0.20 in Q1 2019. Cash and investments increased to $349.0 million. The company maintained its 2020 revenue guidance of $355-375 million. However, COVID-19 has impacted clinical trial enrollments and timelines, but the firm anticipates ongoing developments and results from ongoing trials this year.
Summary not available.